CPP
TEVA icon

Crow Point Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Crow Point Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,706
Closed -$62K – 309
2016
Q4 		$62K Sell
1,706
-1,940
-53% -$77.5K 0.01% 187
2016
Q3 		$169K Buy
+3,646
New +$190K 0.03% 169
2015
Q3 		$399K Sell
7,388
-1,942
-21% -$126K 0.06% 126
2015
Q2 		$504K Buy
9,330
+630
+7% +$38.9K 0.07% 116
2015
Q1 		$470K Buy
+8,700
New +$506K 0.06% 123
2014
Q3 		$391K Buy
7,230
+1,100
+18% +$58.3K 0.05% 149
2014
Q2 		$324K Hold
6,130
– – 0.04% 148
2014
Q1 		$324K Buy
+6,130
New +$283K 0.04% 148

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Crow Point Partners's TEVA Position: Q1 2017 in Review

Crow Point Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 1,706 shares — an estimated $62K sold.

Crow Point Partners first reported a position in TEVA in Q1 2014 and held it in 8 quarters. The position peaked at $504K in Q2 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Crow Point Partners reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Crow Point Partners sold 1,706 Teva Pharmaceuticals shares in Q1 2017, an estimated $62K.
  • Crow Point Partners first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 8 quarters.
  • Crow Point Partners's Teva Pharmaceuticals position peaked at $504K in Q2 2015.
  • 686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Crow Point Partners's 13F filing for Q1 2017, filed 15 May 2017.